These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
682 related articles for article (PubMed ID: 32330574)
1. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574 [TBL] [Abstract][Full Text] [Related]
2. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602 [TBL] [Abstract][Full Text] [Related]
3. Nanobody-photosensitizer conjugates for targeted photodynamic therapy. Heukers R; van Bergen en Henegouwen PM; Oliveira S Nanomedicine; 2014 Oct; 10(7):1441-51. PubMed ID: 24394212 [TBL] [Abstract][Full Text] [Related]
4. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761 [No Abstract] [Full Text] [Related]
9. Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy. Deken MM; Bhairosingh SS; Vahrmeijer AL; Oliveira S Methods Mol Biol; 2022; 2451():547-556. PubMed ID: 35505031 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of [ Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of an Anti-HER2 Nanobody Labeled with Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411 [TBL] [Abstract][Full Text] [Related]
12. Measurement of Cyanine Dye Photobleaching in Photosensitizer Cyanine Dye Conjugates Could Help in Optimizing Light Dosimetry for Improved Photodynamic Therapy of Cancer. James NS; Cheruku RR; Missert JR; Sunar U; Pandey RK Molecules; 2018 Jul; 23(8):. PubMed ID: 30042350 [TBL] [Abstract][Full Text] [Related]
13. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates. van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374 [TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134 [TBL] [Abstract][Full Text] [Related]
15. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Liu X; Luan L; Liu X; Jiang D; Deng J; Xu J; Yuan Y; Xing J; Chen B; Xing D; Huang H Front Immunol; 2023; 14():1292839. PubMed ID: 37954614 [TBL] [Abstract][Full Text] [Related]
16. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121 [TBL] [Abstract][Full Text] [Related]
17. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433 [TBL] [Abstract][Full Text] [Related]
18. Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification. Mashayekhi V; Schooten E; van Bergen En Henegouwen PMP; Kijanka MM; Oliveira S Methods Mol Biol; 2022; 2451():481-493. PubMed ID: 35505026 [TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. Mashayekhi V; Xenaki KT; van Bergen En Henegouwen PMP; Oliveira S Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32977602 [TBL] [Abstract][Full Text] [Related]
20. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging. Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]